Pharmaceutical Care Contributes to Tuberculosis Treatment Adherence and Drug Safety in Indonesia: A Systematic Review
DOI:
https://doi.org/10.26630/jk.v17i2.5884Keywords:
Medication adherence, Medication safety, Pharmaceutical care, Tuberculosis, Drug-related problems (DRP).Abstract
Tuberculosis (TB) remains a major public health challenge in Indonesia, where long-term therapy is complicated by non-adherence and adverse drug events. Patient-centered pharmaceutical care—encompassing counseling, education, monitoring, and medication review—aims to address these therapeutic obstacles. This systematic review evaluated how pharmaceutical care contributes to medication adherence and drug safety among TB patients in Indonesia. Guided by PRISMA 2020, comprehensive searches were conducted across PubMed and Google Scholar (January 2014–June 2026) using Medical Subject Headings (MeSH) and tailored keywords. Primary Indonesian studies investigating pharmacist interventions and reporting adherence, adverse drug reactions (ADRs), or drug-related problems (DRPs) were included. Methodological quality was appraised using Joanna Briggs Institute (JBI) tools. The synthesis included 15 studies across diverse healthcare settings. Ten studies (66.7%) showed that pharmacist-led counseling, education, and monitoring significantly improved medication adherence (e.g., proportion of days covered and MMAS scores). DRPs affected up to 84.34% of patients, predominantly involving drug interactions and hepatotoxicity, with ADRs identified as a primary driver of treatment default. Categorical analyses across quasi-experimental, cohort, and cross-sectional designs confirmed that structured pharmaceutical care enhances treatment compliance and safety surveillance. In conclusion, integrating pharmacists into national TB control programs (DOTS/Puskesmas) is essential to reduce preventable DRPs and optimize therapeutic success.
References
Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., Nahid, P., & Raviglione, M. (2018). Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis. PLoS Medicine, 15(7), e1002595. https://doi.org/10.1371/journal.pmed.1002595
Anggraeni, L., Fajrin, F. A., Machlaurin, A., Prasetyowati, I., & Rahardjo, A. M. (2026). Association between drug related problems and outcomes of tuberculosis patients at Citra Husada Hospital Jember. Jurnal Farmasimed (JFM), 8(2), 976–988. https://doi.org/10.35451/4h3axm73
Aromataris, E., & Munn, Z. (2020). JBI manual for evidence synthesis. Joanna Briggs Institute. https://doi.org/10.46658/JBIMES-20-01
Halim, M., Sabrina, A., & Aris, M. (2023). Kepatuhan pasien TB paru rawat jalan. Jurnal Farmasi IKIFA, 2(1), 30–37. https://doi.org/10.51851/jfi.v2i1.350
Hardianita, T. M., & Nurlaeli, L. (2025). Kepatuhan minum obat anti tuberkulosis pada pasien TB paru. Jurnal Ilmiah Farmasi Indonesia, 3(1), 37–43. https://doi.org/10.33221/jifin.v3i01.4132
Hepler, C. D., & Strand, L. M. (1990). Opportunities and responsibilities in pharmaceutical care. American Journal of Hospital Pharmacy, 47(3), 533–543. https://doi.org/10.1093/ajhp/47.3.533
Karuniawati, H., Putra, O. N., & Wikantyasning, E. R. (2019). Impact of pharmacist counseling and leaflet on the adherence of pulmonary tuberculosis patients in lungs hospital in Indonesia. Indian Journal of Tuberculosis, 66(3), 364–369. https://doi.org/10.1016/j.ijtb.2019.02.015
Lestari, K. S., Wijiastuti, E. A., & Mardhiani, Y. D. (2025). Evaluation of reported anti-tuberculosis drug reactions. Indonesian Journal of Herbal Science and Innovation, 1(2), 89–94. https://e-journal.cendekiasci.id/ijhsi/article/view/9
Müller, A. M., et al. (2018). Interventions to improve adherence to tuberculosis treatment. International Journal of Tuberculosis and Lung Disease, 22(7), 731–740. https://doi.org/10.5588/ijtld.17.0850
Ministry of Health Republic Indonesia. (2020). Strategi nasional penanggulangan tuberkulosis di Indonesia 2020–2024. Jakarta: Minsitry of Health Republic Indonesia. Kementerian Kesehatan Republik Indonesia.
Noviyanto, A., et al. (2024). Pelayanan informasi obat pada pasien tuberkulosis di Puskesmas. Jurnal Farmasi Klinik Indonesia, 11(1), 45–52. https://doi.org/10.47219/ath.v11i1.644
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hrobjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Perwitasari, D. A., et al. (2022). Investigating the relationship between knowledge and hepatotoxic effects with medication adherence of TB patients in Banyumas Regency, Indonesia. International Journal of Clinical Practice, 2022, Article 4044530. https://doi.org/10.1155/2022/4044530
Perwitasari, D. A., et al. (2025). Liver function and medication adherence in tuberculosis patients. Journal of International Medical Research, 53(2), 120–131. https://doi.org/10.1177/03000605251348228
Priyandani, Y., Rahem, A., Athiyah, U., Qomaruddin, M. B., & Kuntoro. (2022). Pharmaceutical care model for antituberculosis drug therapy in tuberculosis patients at primary healthcare centre in Surabaya, Indonesia. Pharmacy Education, 22(2), 263–266. https://doi.org/10.46542/pe.2022.222.263266
Sari, I. D., Yuniar, Y., & Syaripuddin, M. (2014). Studi monitoring efek samping obat antituberkulosis FDC kategori 1. Media Penelitian dan Pengembangan Kesehatan, 24(1), 28–35. https://doi.org/10.22435/mpk.v24i1.3484.28-35
Setiawan, S. I., & Ascobat, P. (2019). Adverse reactions to first-line anti-tuberculosis drugs as a risk factor of pulmonary tuberculosis treatment default in Jakarta, Indonesia. International Journal of Applied Pharmaceutics, 11(Special Issue 6), 80–83. https://doi.org/10.22159/ijap.2019.v11s6.33551
Syafhan, N. F., et al. (2025). Adherence measurement using proportion of days covered in tuberculosis outpatients. Journal of Pharmaceutical Sciences and Community, 22(1), 15–22. http://dx.doi.org/10.52711/0974-360X.2025.00622
Wardani, H. K. (2025, October). Association between Medication Adherence and Tuberculosis Treatment Outcomes: A Retrospective Cohort Study at a Primary Health Center in Kediri, Indonesia. In Proceeding Strada International Conference on Health (pp. 118-125). https://proceeding.thesich.org/index.php/sich/article/view/63
Wijaya, I. N., Nathganeila, L. A., & Priyandani, Y. (2024). The relationship of drug therapy problems and outcome therapy in tuberculosis patients in Surabaya Health Center. Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), 14(3), 222–229. https://doi.org/10.22146/jmpf.98345
World Health Organization. (2025). Global tuberculosis report 2025. Geneva: World Health Organization.
Yulia, K. R., & Andrajati, R. (2021). Oral anti-tuberculosis drugs: An urgent medication reconciliation at hospitals in Indonesia. Journal of Public Health Research, 10(2), 2210. https://doi.org/10.4081/jphr.2021.2210
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ratih Wigatiningsih, Elin Yulinah Sukandar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as this can lead to productive exchanges and earlier and greater citations of published work.
